AI can screen 15 million molecules in a day. It still can’t cure Alzheimer’s.
Summary
Discusses a critical perspective that while AI-driven drug discovery technology is making significant strides, such as shortening the time to identify candidate substances, there is still a long way to go before actual treatments are released to patients.
Key Points
- Novartis researchers used generative AI to quickly narrow down 15 million compounds to 60 candidate substances for Huntington's disease treatment.
- AI has the potential to shorten the early stages of drug discovery by 30-40% and reduce the preclinical candidate development period to around one year.
- However, a large gap still exists between laboratory achievements and treatments delivered to actual patients, and major diseases like Alzheimer's remain unresolved.
- Safety concerns are raised regarding the indiscriminate use of AI for health consultations, with over 40 million people daily searching for symptoms on ChatGPT.
Notable Quotes & Details
Notable Data / Quotes
- Screened 60 compounds out of 15 million
- Preclinical period can be shortened from 3-4 years to 13-18 months
- Average cost of traditional drug development: $2.5 billion
Intended Audience
Pharmaceutical industry stakeholders and general readers interested in medical technology